STSA-1002

N/A

Report date: 2025/09/29 20:01:14

Base Information

Drug NameSTSA-1002

Drug Alias NameSTSA-1002STSA1002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionComplement C5a inhibitors

TargetsComplement C5a

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisRespiratory Distress Syndrome, Adult

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesStaidson(Beijing) Biopharmaceuticals Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesStaidson(Beijing) Biopharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisRespiratory Distress Syndrome, Adult

Inactive IndicationsN/A

Other Information

ATC CodeN/A